Although roughly 41.25% of EGFR-mutant NSCLC recurs at the primary site and these tumors have a heightened propensity for brain metastases [280], many questions remain regarding optimal RT timing, dosing, techniques, and toxicity when combined with osimertinib [280,281]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.